When is the use of second-line tuberculosis (TB) drugs recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

When to Use Second-Line TB Drugs

Second-line TB drugs should be used for patients with drug-resistant tuberculosis, particularly those with rifampicin-resistant TB (RR-TB) or multidrug-resistant TB (MDR-TB), and in cases of serious adverse events to first-line drugs. 1

Primary Indications for Second-Line TB Drugs

  • Confirmed MDR-TB or RR-TB: Second-line drugs are required when resistance to both isoniazid and rifampicin (MDR-TB) or rifampicin alone (RR-TB) is confirmed through molecular or phenotypic drug susceptibility testing (DST) 1
  • Extensively drug-resistant TB (XDR-TB): Treatment with new medicines including bedaquiline and delamanid along with repurposed medicines like linezolid and clofazimine is required for patients with XDR-TB 1
  • Resistance to fluoroquinolones or second-line injectables: Patients with resistance to these drugs require specialized regimens with new and repurposed drugs 1
  • Serious adverse events to first-line drugs: When patients cannot tolerate first-line medications, second-line drugs may be necessary as alternatives 1

Drug Selection for MDR/RR-TB Regimens

Longer Regimens (18-20 months)

For individualized longer regimens, drugs should be selected according to the following hierarchy 1, 2:

  1. Group A (include all when possible):

    • Levofloxacin or Moxifloxacin
    • Bedaquiline
    • Linezolid 2
  2. Group B (add one or both):

    • Clofazimine
    • Cycloserine 2
  3. Group C (add to complete regimen when drugs from Groups A and B cannot be used):

    • Ethambutol
    • Delamanid
    • Pyrazinamide (if susceptibility confirmed)
    • Ethionamide/Prothionamide
    • p-aminosalicylic acid 1, 2

Shorter MDR-TB Regimen (9-11 months)

A shorter MDR-TB regimen may be used when 1, 3:

  • Patient has not been previously treated with second-line drugs for more than 1 month
  • Resistance to fluoroquinolones and second-line injectable agents has been excluded
  • No intolerance to any medicine in the shorter regimen
  • No pregnancy
  • No extrapulmonary disease
  • All medicines in the regimen are available 1

Contraindications to Shorter Regimens

Do not use the shorter MDR-TB regimen when 1, 3:

  • Confirmed resistance to any medicine in the shorter regimen
  • Previous exposure to second-line medicines for >1 month
  • Intolerance to medicines in the regimen
  • Pregnancy
  • Extrapulmonary TB
  • Unavailability of any medicine in the regimen 1

Important Principles for Second-Line TB Treatment

  • Never add a single effective drug to a failing regimen as this promotes development of further drug resistance 1, 2
  • Regimens should include at least five effective TB medicines during the intensive phase for longer regimens 1
  • Treatment decisions should be made by a team of experts rather than individual physicians to minimize mistakes and share expertise 1
  • Regular monitoring of treatment response through monthly sputum smear and culture is essential 1, 2
  • Adverse events should be managed according to international recommendations to prevent discontinuation of effective drugs 1, 4

Special Considerations

  • HIV co-infection: Antiretroviral therapy should be started as early as possible (within the first 8 weeks) following initiation of anti-TB treatment 1, 5
  • Surgical intervention: Elective partial lung resection may be considered in selected cases with pulmonary TB, especially those with large cavities confined to one lobe 1
  • Drug susceptibility testing: Second-line DST should be performed to confirm the drug resistance pattern and guide the correct choice of treatment 1, 6

Common Pitfalls to Avoid

  • Inadequate regimen design: Using too few effective drugs increases risk of treatment failure and further resistance 1, 7
  • Poor monitoring: Failure to monitor for adverse effects can lead to poor adherence and treatment failure 4, 1
  • Delayed DST: Not performing rapid DST for second-line drugs can lead to ineffective treatment and resistance amplification 6, 5
  • Standardized regimens without DST: Using standardized regimens without knowledge of resistance patterns can worsen outcomes 8, 7

Second-line TB drugs require careful selection based on resistance patterns, patient history, and monitoring for adverse effects to ensure optimal outcomes and prevent further drug resistance.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Recommended Longer Oral Regimen for Drug-Resistant Tuberculosis (DR-TB)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Empirical Antitubercular Drug Extended 9-Month Regimen

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Diagnosis and treatment of multidrug-resistant tuberculosis.

Yeungnam University journal of medicine, 2020

Research

Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2017

Research

New drugs and regimens for tuberculosis.

Respirology (Carlton, Vic.), 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.